Actinium Pharmaceuticals (ATNM) Other Non Operating Income (2012 - 2018)
Actinium Pharmaceuticals (ATNM) posted quarterly Other Non Operating Income of $9076.0 for Q1 2018, up 103.55% year-over-year from $4459.0 in Q1 2017, and down 76.37% quarter-over-quarter from $38409.0 in Q4 2017.
Actinium Pharmaceuticals (ATNM) Other Non Operating Income (2012 - 2018) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Other Non Operating Income for 7 consecutive years, with $9076.0 the latest figure, recorded in Q1 2018.
- In Q1 2018, Other Non Operating Income rose 103.55% year-over-year to $9076.0; the TTM figure through Mar 2018 stood at $569194.0 (down 15.47% YoY), while the FY2017 annual figure was $304123.0, down 87.98% from the prior year.
- Other Non Operating Income retreated to $9076.0 in Q1 2018 per ATNM's latest filing, from $38409.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $7.9 million in Q2 2014 and bottomed at -$12.6 million in Q1 2014.
- Historically, Other Non Operating Income has averaged $261775.4 across 5 years, with a median of $295462.0 in 2016.
- On a YoY basis, Other Non Operating Income climbed as much as 707.13% in 2014 and fell as far as 1041.25% in 2014.
- Actinium Pharmaceuticals' Other Non Operating Income stood at $1.4 million in 2014, then tumbled by 211.97% to -$1.6 million in 2015, then jumped by 108.09% to $131125.0 in 2016, then tumbled by 70.71% to $38409.0 in 2017, then plunged by 76.37% to $9076.0 in 2018.
- Business Quant data shows ATNM's Other Non Operating Income at $9076.0 in Q1 2018, $38409.0 in Q4 2017, and $372117.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 9,076.00 |
| Dec 31, 2017 | 38,409.00 |
| Sep 30, 2017 | 372,117.00 |
| Jun 30, 2017 | 149,592.00 |
| Mar 31, 2017 | -255,995.00 |
| Dec 31, 2016 | 131,125.00 |
| Sep 30, 2016 | 502,778.00 |
| Jun 30, 2016 | 295,462.00 |
| Mar 31, 2016 | 1.60 Mn |
| Dec 31, 2015 | -1.62 Mn |
| Sep 30, 2015 | 694,208.00 |
| Jun 30, 2015 | -57,668.00 |
| Mar 31, 2015 | 4.80 Mn |
| Dec 31, 2014 | 1.45 Mn |
| Sep 30, 2014 | 967,887.00 |
| Jun 30, 2014 | 7.94 Mn |
| Mar 31, 2014 | -12.56 Mn |
| Dec 31, 2013 | -4.40 Mn |
| Sep 30, 2013 | 189,348.00 |
| Jun 30, 2013 | -1.31 Mn |